

**Dry Age-Related Macular Degeneration Market Size, Share & Trends Analysis Report  
By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related  
Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group  
(Above 75 Years, Above 60 Years, Above 40 Years), By Route of Administration (Oral,  
Injectable), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail  
Pharmacies, Online Pharmacies) and By Region(North America, Europe, APAC, Middle  
East and Africa, LATAM) Forecasts, 2024-2032**

Market Report | 2023-04-06 | 0 pages | Straits Research

**AVAILABLE LICENSES:**

- Single User License \$4500.00
- Global Site License \$5500.00

**Report description:**

Dry Age-Related Macular Degeneration Market Analysis and Insights

The Dry Age-Related Macular Degeneration Market size is anticipated to reach USD 1,767.74 million in 2023 and it is projected to reach USD 3,375.56 million by 2032, growing at a CAGR of % during the forecast period.

The Global Dry Age-Related Macular Degeneration Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Dry Age-Related Macular Degeneration Market growth, Size report provides a comprehensive analysis of the Healthcare IT industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing. Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Experts, Dry Age-Related Macular Degeneration Market includes major suppliers & Independent Consultants among others.

#### Global Market Scope and Dry Age-Related Macular Degeneration Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Dry Age-Related Macular Degeneration Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

#### Dry Age-Related Macular Degeneration Market Country Level Analysis

The Global Dry Age-Related Macular Degeneration Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Dry Age-Related Macular Degeneration Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

#### Top Players in Dry Age-Related Macular Degeneration Market

Some of the other major highlights of the demand for Dry Age-Related Macular Degeneration Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Dry Age-Related Macular Degeneration Market during the forecast period.

Apellis Pharmaceuticals, Inc

Astellas Pharma Inc. (Iveric Bio)

Hoffmann-La Roche AG (Genentech, Inc.)

Disc Medicine, Inc. (Gemini Therapeutics, Inc.)

Ionis Pharmaceuticals

NGM Biopharmaceuticals

Annexon Biosciences

AstraZeneca (Alexion Pharmaceuticals)

Boehringer Ingelheim

ONL Therapeutics

Biogen

Novartis AG

Stealth Biotherapeutics Corp.

#### Market Segmentation

The Global Dry Age-Related Macular Degeneration Market Share, Demand provides the most up-to-date Healthcare IT industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

#### By Stage

Early Age-Related Macular Degeneration

Intermediate Age-Related Macular Degeneration

Late Age-Related Macular Degeneration

#### By Age Group

Above 75 Years

Above 60 Years

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Above 40 Years

By Route of Administration

Oral

Injectable

By Distribution Channel

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Pharmacies

Regions Coverd

North America

U.S.

Canada

Europe

U.K.

Germany

France

Spain

Italy

Russia

Nordic

Benelux

Rest of Europe

APAC

China

Korea

Japan

India

Australia

Singapore

Taiwan

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

South East Asia  
Rest of Asia-Pacific

Middle East and Africa

UAE  
Turkey  
Saudi Arabia  
South Africa  
Egypt  
Nigeria  
Rest of MEA

LATAM

Brazil  
Mexico  
Argentina  
Chile  
Colombia  
Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

**Table of Contents:**

- 1 Executive Summary
- 2 Research Scope & Segmentation
  - 2.1 Research Objectives
  - 2.2 Limitations & Assumptions
  - 2.3 Market Scope & Segmentation
  - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
  - 3.1 Emerging Regions / Countries
  - 3.2 Emerging Companies
  - 3.3 Emerging Applications / End Use
- 4 Market Trends
  - 4.1 Drivers
  - 4.2 Market Warning Factors

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.3 Latest Macro Economic Indicators
- 4.4 Geopolitical Impact
- 4.5 Technology Factors
- 5 Market Assessment
  - 5.1 Porters Five Forces Analysis
  - 5.2 Value Chain Analysis
- 6 Global Dry Age-Related Macular Degeneration Market Size Analysis
  - 6.1 By Stage
    - 6.1.1 Early Age-Related Macular Degeneration
    - 6.1.2 Intermediate Age-Related Macular Degeneration
    - 6.1.3 Late Age-Related Macular Degeneration
  - 6.2 By Age Group
    - 6.2.1 Above 75 Years
    - 6.2.2 Above 60 Years
    - 6.2.3 Above 40 Years
  - 6.3 By Route of Administration
    - 6.3.1 Oral
    - 6.3.2 Injectable
  - 6.4 By Distribution Channel
    - 6.4.1 Hospital Pharmacies
    - 6.4.2 Drug Stores and Retail Pharmacies
    - 6.4.3 Online Pharmacies
- 7 North America Market Analysis
  - 7.1 By Stage
    - 7.1.1 Early Age-Related Macular Degeneration
    - 7.1.2 Intermediate Age-Related Macular Degeneration
    - 7.1.3 Late Age-Related Macular Degeneration
  - 7.2 By Age Group
    - 7.2.1 Above 75 Years
    - 7.2.2 Above 60 Years
    - 7.2.3 Above 40 Years
  - 7.3 By Route of Administration
    - 7.3.1 Oral
    - 7.3.2 Injectable
  - 7.4 By Distribution Channel
    - 7.4.1 Hospital Pharmacies
    - 7.4.2 Drug Stores and Retail Pharmacies
    - 7.4.3 Online Pharmacies
  - 7.4 U.S.
  - 7.5 Canada
- 8 Europe Market Analysis
  - 8.1 By Stage
    - 8.1.1 Early Age-Related Macular Degeneration
    - 8.1.2 Intermediate Age-Related Macular Degeneration
    - 8.1.3 Late Age-Related Macular Degeneration
  - 8.2 By Age Group
    - 8.2.1 Above 75 Years

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2.2 Above 60 Years
- 8.2.3 Above 40 Years
- 8.3 By Route of Administration
  - 8.3.1 Oral
  - 8.3.2 Injectable
- 8.4 By Distribution Channel
  - 8.4.1 Hospital Pharmacies
  - 8.4.2 Drug Stores and Retail Pharmacies
  - 8.4.3 Online Pharmacies
- 8.4 U.K.
- 8.5 Germany
- 8.6 France
- 8.7 Spain
- 8.8 Italy
- 8.9 Russia
- 8.10 Nordic
- 8.11 Benelux
- 8.12 Rest of Europe
- 9 APAC Market Analysis
  - 9.1 By Stage
    - 9.1.1 Early Age-Related Macular Degeneration
    - 9.1.2 Intermediate Age-Related Macular Degeneration
    - 9.1.3 Late Age-Related Macular Degeneration
  - 9.2 By Age Group
    - 9.2.1 Above 75 Years
    - 9.2.2 Above 60 Years
    - 9.2.3 Above 40 Years
  - 9.3 By Route of Administration
    - 9.3.1 Oral
    - 9.3.2 Injectable
  - 9.4 By Distribution Channel
    - 9.4.1 Hospital Pharmacies
    - 9.4.2 Drug Stores and Retail Pharmacies
    - 9.4.3 Online Pharmacies
  - 9.4 China
  - 9.5 Korea
  - 9.6 Japan
  - 9.7 India
  - 9.8 Australia
  - 9.9 Taiwan
  - 9.10 South East Asia
  - 9.11 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
  - 10.1 By Stage
    - 10.1.1 Early Age-Related Macular Degeneration
    - 10.1.2 Intermediate Age-Related Macular Degeneration
    - 10.1.3 Late Age-Related Macular Degeneration

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.2 By Age Group
  - 10.2.1 Above 75 Years
  - 10.2.2 Above 60 Years
  - 10.2.3 Above 40 Years
- 10.3 By Route of Administration
  - 10.3.1 Oral
  - 10.3.2 Injectable
- 10.4 By Distribution Channel
  - 10.4.1 Hospital Pharmacies
  - 10.4.2 Drug Stores and Retail Pharmacies
  - 10.4.3 Online Pharmacies
- 10.4 UAE
- 10.5 Turkey
- 10.6 Saudi Arabia
- 10.7 South Africa
- 10.8 Egypt
- 10.9 Nigeria
- 10.10 Rest of MEA
- 11 LATAM Market Analysis
  - 11.1 By Stage
    - 11.1.1 Early Age-Related Macular Degeneration
    - 11.1.2 Intermediate Age-Related Macular Degeneration
    - 11.1.3 Late Age-Related Macular Degeneration
  - 11.2 By Age Group
    - 11.2.1 Above 75 Years
    - 11.2.2 Above 60 Years
    - 11.2.3 Above 40 Years
  - 11.3 By Route of Administration
    - 11.3.1 Oral
    - 11.3.2 Injectable
  - 11.4 By Distribution Channel
    - 11.4.1 Hospital Pharmacies
    - 11.4.2 Drug Stores and Retail Pharmacies
    - 11.4.3 Online Pharmacies
  - 11.4 Brazil
  - 11.5 Mexico
  - 11.6 Argentina
  - 11.7 Chile
  - 11.8 Colombia
  - 11.9 Rest of LATAM
- 12 Competitive Landscape
  - 12.1 Global Dry Age-Related Macular Degeneration Market Share By Players
  - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
  - 13.1 American International Industries (GIGI)
    - 13.1.1 Overview
    - 13.1.2 Business Information

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.1.3 Revenue
- 13.1.4 ASP
- 13.1.5 Swot Analysis
- 13.1.6 Recent Developments
- 13.2 Astellas Pharma Inc. (Iveric Bio)
- 13.3 Hoffmann-La Roche AG (Genentech, Inc.)
- 13.4 Disc Medicine, Inc. (Gemini Therapeutics, Inc.)
- 13.5 Ionis Pharmaceuticals
- 13.6 NGM Biopharmaceuticals
- 13.7 Annexon Biosciences
- 13.8 AstraZeneca (Alexion Pharmaceuticals)
- 13.9 Boehringer Ingelheim
- 13.10 ONL Therapeutics
- 13.11 Biogen
- 13.12 Novartis AG
- 13.13 Stealth Biotherapeutics Corp.
- 14 Research Methodology
  - 14.1 Research Data
    - 14.1.1 Secondary Data
      - 14.1.1.1 Major secondary sources
      - 14.1.1.2 Key data from secondary sources
    - 14.1.2 Primary Data
      - 14.1.2.1 Key data from primary sources
      - 14.1.2.2 Breakdown of primaries
  - 14.1.3 Secondary And Primary Research
    - 14.1.3.1 Key industry insights
  - 14.2 Market Size Estimation
    - 14.2.1 Bottom-Up Approach
    - 14.2.2 Top-Down Approach
    - 14.2.3 Market Projection
  - 14.3 Research Assumptions
    - 14.3.1 Assumptions
  - 14.4 Limitations
  - 14.5 Risk Assessment
- 15 Appendix
  - 15.1 Discussion Guide
  - 15.2 Customization Options
  - 15.3 Related Reports
- 16 Disclaimer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Dry Age-Related Macular Degeneration Market Size, Share & Trends Analysis Report  
By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related  
Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group  
(Above 75 Years, Above 60 Years, Above 40 Years), By Route of Administration (Oral,  
Injectable), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail  
Pharmacies, Online Pharmacies) and By Region(North America, Europe, APAC, Middle  
East and Africa, LATAM) Forecasts, 2024-2032**

Market Report | 2023-04-06 | 0 pages | Straits Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Job title\*

Company Name\*

Address\*

Zip Code\*

EU Vat / Tax ID / NIP number\*

City\*

Country\*

Date

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com